Oppenheimer Assumes Allogene Therapeutics at Outperform, Announces Price Target of $28
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes Allogene Therapeutics (NASDAQ:ALLO) with an Outperform rating and announces a price target of $28.
June 26, 2023 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer assumes Allogene Therapeutics with an Outperform rating and a price target of $28.
The Outperform rating and price target of $28 by Oppenheimer analyst Mark Breidenbach indicate a positive outlook for Allogene Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100